Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic avenue for managing metabolic disorders. These naturally occurring substances are secreted by the gut in response to meal intake, stimulating insulin production and suppressing glucagon secretion. GLP-1 derivatives demonstrate promising therapeutic efficacy in treating